Table 6. Univariate analysis results of OS and RFS.
| Variables | OS univariate | RFS univariate | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | ||
| Sex | |||||||
| Female (n=66) | 1.000 | 0.294 | 1.000 | 0.392 | |||
| Male (n=386) | 1.219 | 0.842–1.766 | 1.152 | 0.833–1.595 | |||
| Patient age (y) | |||||||
| <65 (n=377) | 1.000 | 0.618 | 1.000 | 0.837 | |||
| ≥65 (n=75) | 1.084 | 0.790–1.486 | 1.032 | 0.768–1.386 | |||
| Diabetes | |||||||
| No (n=401) | 1.000 | 0.327 | 1.000 | 0.413 | |||
| Yes (n=51) | 0.819 | 0.550–1.221 | 0.864 | 0.608–1.227 | |||
| Cardiovascular disease | |||||||
| No (n=353) | 1.000 | 0.027 | 1.000 | 0.239 | |||
| Yes (n=99) | 1.370 | 1.036–1.811 | 1.169 | 0.901–1.515 | |||
| HBsAg | |||||||
| Negative (n=67) | 1.000 | 0.377 | 1.000 | 0.205 | |||
| Positive (n=385) | 1.175 | 0.822–1.678 | 1.227 | 0.887–1.698 | |||
| Child-Pugh classification | |||||||
| A (n=431) | 1.000 | 0.512 | 1.000 | 0.228 | |||
| B (n=21) | 1.214 | 0.680–2.168 | 1.363 | 0.824–2.254 | |||
| AFP (ng/mL) | |||||||
| <400 (n=294) | 1.000 | <0.001 | 1.000 | <0.001 | |||
| ≥400 (n=158) | 2.151 | 1.682–2.751 | 1.896 | 1.513–2.376 | |||
| Tumor size (cm) | |||||||
| <5.0 (n=200) | 1.000 | <0.001 | 1.000 | <0.001 | |||
| ≥5.0 (n=252) | 2.824 | 2.166–3.681 | 2.418 | 1.918–3.049 | |||
| Number of tumors | |||||||
| Solitary (n=356) | 1.000 | <0.001 | 1.000 | <0.001 | |||
| Multiple (n=96) | 1.743 | 1.326–2.291 | 1.702 | 1.324–2.189 | |||
| Tumor differentiation | |||||||
| Well (n=42) | 1.000 | 0.305 | 1.000 | 0.243 | |||
| Moderate (n=327) | 1.334 | 0.850–2.094 | 0.211 | 1.032 | 0.866–1.230 | 0.725 | |
| Poor (n=83) | 1.493 | 0.897–2.487 | 0.123 | 1.196 | 0.965–1.484 | 0.103 | |
| Microvascular invasion | |||||||
| Negative (n=290) | 1.000 | <0.001 | 1.000 | <0.001 | |||
| Positive (n=162) | 2.293 | 1.791–2.935 | 1.764 | 1.407–2.212 | |||
| Macrovascular invasion | |||||||
| Negative (n=386) | <0.001 | 1.000 | <0.001 | ||||
| PVTT (n=50) | 4.042 | 2.914–5.606 | <0.001 | 3.097 | 2.239–4.238 | <0.001 | |
| HVTT (n=8) | 4.113 | 1.929–8.770 | <0.001 | 5.562 | 2.720–11.377 | <0.001 | |
| PVTT + HVTT (n=8) | 3.641 | 1.708–7.763 | <0.001 | 2.888 | 1.360–6.132 | 0.006 | |
| Complete encapsulation | |||||||
| Positive (n=7) | 1.000 | 0.927 | 1.000 | 0.382 | |||
| Negative (n=445) | 1.047 | 0.390–2.812 | 1.398 | 0.660–2.961 | |||
| Satellite lesions | |||||||
| Negative (n=428) | 1.000 | 0.001 | 1.000 | <0.001 | |||
| Positive (n=24) | 2.230 | 1.411–3.524 | 2.532 | 1.650–3.886 | |||
| AJCC | |||||||
| I (n=213) | 1.000 | <0.001 | 1.000 | <0.001 | |||
| II (n=98) | 1.711 | 1.217–2.404 | <0.001 | 1.559 | 1.160–2.096 | 0.003 | |
| III (n=135) | 4.979 | 3.728–6.650 | <0.001 | 4.606 | 3.573–5.998 | <0.001 | |
| IV (n=6) | 13.093 | 5.613–30.539 | <0.001 | 5.852 | 2.369–14.454 | <0.001 | |
| SOLMR grade | |||||||
| A (OS: n=138; RFS: n=126) | 1.000 | <0.001 | 1.000 | <0.001 | |||
| B (OS: n=279; RFS: n=291) | 2.890 | 2.077–4.020 | 2.664 | 1.989–3.569 | |||
| C (n=35) | 8.671 | 5.439–13.821 | 5.219 | 3.360–8.107 | |||
OS, overall survival; RFS, recurrence-free survival; HR, hazard ratio; CI, confidence interval; HBsAg, hepatitis B surface antigen; AFP, alpha-fetoprotein; PVTT, portal vein tumor thrombus; HVTT, hepatic vein tumor thrombus; BDTT, bile duct tumor thrombus; AJCC, American Joint Committee Cancer 8th of HCC; HCC, hepatocellular carcinoma.